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ABSTRACT 
Inflammatory Bowel Disease is a complex, non-Mendelian auto-inflammatory/auto-immune 
disorder with increasing incidence worldwide.  The pathogenesis of this disease remains elusive; 
however, the current theory postulates that the inflammation of the bowel is caused by an aberrant 
immune response to commensal gut bacterial.  It is believed that this abnormal response occurs in 
a genetically susceptible host after exposure to environmental triggers. Research has still yet to 
prove a universal trigger for all cases of IBD  
Currently the genotype-phenotype data is too limited to provide any kind of substantial 
diagnostic genetic test and relative risk data provides as 1 in 10-20 risk for first-degree family 
members.  Roughly 20-25% of disease heritability is explained and researchers believe an 
additional portion of the “missing heritability” may be found in either risk alleles with small effect 
sizes or the non-coding regions of the genome affecting gene expression through gene-to-gene 
interactions. 
Studies have shown patients are open and receptive to genetic counseling services; 
however, today’s data provides counselors with little useful information but does not rule out the 
need for genetic counseling services.  In the future a panel of many small effect genes may help to 
elucidate those at the greatest risk for disease.   
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The ability to determine those at the greatest risk for disease is of public health importance 
due to the ever-increasing burden of disease.  With the average age of onset between 15-30 years 
old, the majority of an individual’s working life may be inhibited by disease related complications 
reducing their productivity, as well as, increasing the time and cost for which disease related health 
care services are required.  Together these factors and more create a burden of disease on both the 
individual and the public health community.   
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PREFACE 
This thesis comes one year after the onset of my IBD symptoms and since then my life 
has not been the same.  It wasn’t until I was hospitalized in January 2014 that I was given the 
diagnosis of ulcerative colitis.  I wrote this not just as a graduate student or a researcher but also 
as a patient trying to understand why this happened to me.  This was not an easy journey for me, 
and some potholes were significantly larger than others; however, I made it.  
Thank you to my parents for their unconditional love and support.  Thank you Ryan for 
so many things but especially for cross-country flights, multiple trips to the hospital, for telling 
me to keep going and to “just send it”.  Thank you to my girls, to the best friends anyone could 
ask for, the one thing that made the last two years worth it. 
Thank you to Dr. Binion for finally getting me well.  Thank you Dr. Shaffer for all his 
edits.  Thank you to Dr. Finegold who taught me not just about the inner workings of life, but 
also about how life works.  Sometimes, people are potholes, but that should never stop me from 
driving. 
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1.0  INTRODUCTION 
Inflammatory Bowel Disease (IBD) can be clinically defined, in the most simple of terms, as a 
chronic inflammation of the gastrointestinal tract. The majority of IBD individuals fall into two 
diagnostic categories: Crohn’s Disease (CD) or Ulcerative Colitis (UC).  In regards to histology 
and the location of inflammation the two disorders are unique.  However, in their ability to 
negatively affect the quality of an individual’s life they are the same.   
IBD is known for its alternating periods of inactive and active inflammation known as 
remissions and relapses or flares (Ananthakrishnan 2013; Conrad et al. 2014; Thompson et al. 
2011; Ordas et al. 2012).  An active flare state is when a person with IBD is actively 
experiencing symptoms which can consists of: general feelings of being ill, diarrhea, rectal 
bleeding, bloody stools, urgent bowel movements, frequent bowel movements, constipation, 
abdominal cramps and pain, fever, fatigue, or weight loss.   
Flares can range in their severity and presentation depending both on the individual and 
the type of IBD.   A mild or moderate UC flare may consist of mild diarrhea and urgent bowel 
movements once or twice a day.   A severe UC flare may cause extreme abdominal pain, 10 to 
12 bowel movements in a few hours, with feelings of incomplete evacuation or tenesmus, along 
with blood and/or pus and/or mucous in the stool.   
CD differs from UC in that it often affects the small intestine and the inflammation 
penetrates into the deeper layers of the gastrointestinal wall.  This often leads to the formation of 
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fistulas, which are sores that extend through the GI wall to other organs.  A severe CD flare may 
consist of both weight and appetite loss, anal fissures, severe pain after eating, tenesmus, 
multiple bowel movements in a day and bloody diarrhea.   
In efforts to find a cure for this debilitating disease researchers are still attempting to 
understand what causes it.  However the pathogenesis, the mechanism(s) of disease, and the 
etiology, the factors that instigate the onset of disease, are still being elucidated. 
The current working model of IBD’s pathogenesis, presents a complex disease in which a 
dysregulated mucosal immune response to intestinal microbial flora in a genetically susceptible 
host, triggered by as yet to be determined environmental factors (Zhang and Li 2014; Hanauer 
2006).  
When individuals harboring IBD risk alleles are exposed to certain environmental triggers, 
their ability to correctly respond to commensal and pathogenic microbes in the gut is compromised.  
This altered microbial reaction, results in an improper immune response that sets off an 
unregulated and ill controlled inflammatory cascade.  Currently, a large portion of the risk loci 
being investigated are linked to infection susceptibility, host-microbial response, and show overlap 
with other autoimmune diseases further strengthening the concept that IBD is an intricate 
communication error between the bacterial of the gut and the intestinal immune system 
(Ananthakrishnan 2013). Risk alleles have been found in genes that are associated with innate 
immune pathways (i.e. Th17 cells, CARD9, NOD2, reactive oxygen species and IL-1β) (Knights 
et al 2013).  
While IBD is considered an auto-inflammatory disease it also shares the largest number of 
risk loci with the autoimmune disease diabetes type I; as well as, a significant number of loci with 
other auto-immune diseases such as: ankylosing spondylitis, an arthritis of the spine, and psoriasis, 
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which causes irritated, red, flaky patches of skin (Graham and Xavier 2013).  These diseases share 
risk loci in pathways such as antigen presentation and intestinal mucosal homeostasis (Knights et 
al. 2013).   
A significant amount of research has been spent investigating the link between genetic 
mutations in the intestinal immune system and the composition of the microbiome, particularly at 
the onset of disease.  Questioning whether a change in the homeostasis of the commensal bacteria, 
possibly an increase in a particular type of bacteria triggers this aggressive immune response 
(Knights et al. 2013; Jostins et al. 2012; Xavier and Podolsky 2007; Ananthakrishnan 2013).   
Another theory is that host tolerance is somehow lost to normal gut microbes, causing harmless 
microbes to be inadvertently labeled as pathogenic and triggering an unnecessary immune 
response (Hanauer 2006).   
Researchers have cast a wide net in an attempt to discern environmental triggers that 
precede the onset of IBD, particularly in conjunction with their connection to the microbiome.  
There is evidence, that prior gastrointestinal infections, as well as exposure to antibiotics, 
especially before the age of one, may increase risk of developing IBD.  However, not all 
environmental triggers uniformly affect all forms of IBD. For example, while cigarette exposure 
acts as a risk factor for CD, it alternately acts as a protective factor for UC, or while having an 
appendectomy has been associated as a protective factor for UC, it has no effect on the 
development of CD. Diet and lifestyle have also been investigated with some research suggesting 
that diets high in fat and low in soluble fiber are associated with increased risk for the development 
of IBD.  Additionally, it is believed that geographic location may play a role as there is some 
association with a north south gradient, with a greater incidence of IBD linked to those individuals 
living in more northern areas, where a relative decrease in UV exposure may connect these 
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individuals to the finding that those with IBD tend to be vitamin D deficient  (Mouli and 
Ananthakrishnan 2014; Ng et al 2013). 
While some individuals who suffer from IBD are able to identify their own personal 
triggers, such as particular foods or activities and can reduce their symptoms by avoiding these, 
there is no consensus on which environmental triggers are universal, as studies have only produced 
ambiguity. Without knowing the factors that precipitate IBD or the underlying pathology it is 
difficult to enact preventative measures to decrease the risk for disease in susceptible individuals.   
Therefore medicine must currently focus on treatments that target symptoms. 
Current treatment modalities do not result in universal remission and many have serious 
side effects.  Therapy is determined based on disease type, severity and location.  Anti-
inflammatories, steroids, and antibiotics are usually the first lines of defense for mild to moderate 
disease.  In cases of severe disease immunosuppressive medications may be used, as well as two 
types of biologic therapy: anti-TNF agents which block the protein tumor necrosis factor alpha, 
i.e. infliximab, adalimumab, and anti-integrins used to block integrins, which are proteins used by 
white blood cells to travel to areas of active inflammation, such as the intestine, i.e. natalizumab.   
If the inflammation cannot be controlled, surgical removal of the affected bowel is another 
treatment option with CD patients up to 3 times more likely than UC patients to require surgery  
(Hanauer 2006).  
While removal of the bowel is not ideal, the improvement in quality of life can be 
substantial.  Life after surgery is a common topic among members of Internet-based support 
groups.  The “Crohn’s and Colitis UK” Facebook group is just one of the many online support 
resources for those with IBD.  It is an open forum to discuss all aspects of life with IBD, and many 
members use it to share their surgery experiences.   “Get Your Belly Out” is an online movement 
 4 
where individuals who have colostomy bags proudly post photos displaying their bags or surgical 
scares and share their stories with followers.  The sharing of trials, tribulations, and treatment 
successes with others  helps to improve confidence and tear down some of the stigma of life after 
surgery.       
Without an identified cause(s) it is difficult for individuals to control the timing and 
duration of flares.  The two most disruptive symptoms are pain and frequent, urgent bowel 
movements; which can severely affect the quality of every day life.  
IBD can occur at any age; however, it often strikes individuals during their early formative 
years, the major peak of onset occurring between 15 and 30 years old , meaning most individuals 
affected by IBD suffer for more than two thirds of their lifespan (Hanauer  2006; Ordas et al. 2012; 
Molodecky et al. 2012).   An earlier onset also inhibits individuals during their most productive 
years, diminishing their capacity to be active, productive members of society  (Ng et al. 2013). 
Boonen et al. (2002) studied Dutch IBD patients and their presence and ability to 
participate in the labor force.  They found the labor force participation of IBD individuals was 
6.5% lower than controls and the amount of chronic work disability was 17.1% higher, with CD 
patients being more affected than UC patients. Boonen et al. (2002) also adjusted for age, gender, 
and education, and found the odds ratio (OR) of chronic work disability in UC relative to controls 
was 2.6  (95% CI: 1.8–3.6) and 5.4 (95% CI: 3.7–7.8) in CD.  Additionally, IBD individuals had 
higher numbers for disease-related sick days than controls and also often had lower numbers of 
non-disease-related sick leave compared to controls.   Boonen et al. (2002) suggests that those with 
IBD are aware of the need to utilize sick days for disease related illness and so may consciously 
choose to work through minor illness to a lot for that fact.  
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Because of current detection and treatment modalities, IBD does not increase mortality to 
the point of decreasing the expected lifespan, resulting in an increased burden of disease not only 
for the individual but the community at large (Hanauer 2006; Ordas et al. 2012). 
The Crohn’s & Colitis Federation of America (CCFA) website, when accessed in April 
2014 states that 1 in 200 Americans suffers from IBD. Hanauer (2006) discussed the burden of 
disease in the US, stating, IBD patients generate 700,000 physician visits, and 100,000 
hospitalizations with 119,000 IBD patients considered disabled by their disease, annually.  This 
data was taken from the National Institute of Diabetes and Digestive and Kidney Diseases 
epidemiological impact report from 1994.  As the incidence of this disease has increased since 
then, about 30,000 new cases per year, these numbers are most likely an underestimate of the 
burden of disease today.  Loftus (2007) stated that the likely prevalence of IBD in the US was 
somewhere between 1 million and 1.5 million. The cost of medications, endoscopies, 
colonoscopies, and hospital admissions can be staggering.  According to the Centers for Disease 
Control website, www.CDC.gov, accessed in April of 2014, the overall health care cost for IBD 
is $1.7 billion.   In 2008 the National Institute of Diabetes and Digestive and Kidney Disease 
investigated the burden of prescription medications associated with IBD, Table 1. below presents 
that  information.  However, the data is limited by the following: not all medications used for the 
treatment of IBD were investigated and the data was collected from retail pharmacies only.  
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Table 1. 2004 IBD Prescription Data 
Data from 2004 UC CD Total 
Number of Prescriptions 2,181,622 1,878,368 4,059,990 
Retail Cost $272,893,060 $261,504,663 $534,397,723 
 
The incidence of IBD is steadily increasing around the world, with a current worldwide 
prevalence of 2.5 million people (Dinwiddie et al 2013).  IBD is most commonly found in North 
America and Europe, but has also been seen in Israel, Australia, and South Africa.  IBD, more so 
UC, is becoming more prevalent in places like Japan, South Korea, Singapore, northern India, and 
Latin America where previously it was a rare occurrence (Loftus 2004; Ng et al. 2013). 
Many researchers have discovered a positive correlation between an increase in an 
“industrialized” or “westernized” lifestyle, occurring in the areas previously mentioned, and the 
incidence of IBD.  This finding supports the role of environmental factors in the development of 
IBD (Ordas et al. 2012). 
Because environmental factors alone do not appear to cause IBD deeper investigation into 
the genetics of IBD is warranted.  Familial clustering and monozygotic concordance rates in twin 
studies support the existence of a genetic component. Recent advances in Genome Wide 
Association studies (GWAS) and Immunochip studies (specifically designed SNP chip arrays) 
have significantly increased our understanding of the possible genes and pathways involved in 
IBD.  The number of risk loci currently stands at 163, associated with 300 known genes, however, 
these loci currently explain 20-25% of disease heritability (Jostins et al. 2012).  The remaining 
“missing heritability” is postulated to be laying in wait: 1. in SNPs with only modest evidence of 
This table displays the number of prescriptions written and the totally cost of those prescriptions by disease 
type in the US in 2004. The table was adapted from the 2008 report from the National Institutes of Health, 
National Institute of Diabetes and Digestive and Kidney Diseases.   The data is limited as is does not include 
all medications used to treat IBD and was collected from retail pharmacies only.    
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association or 2. in gene-to-gene interactions (Duerr 2007; Zhang and Li 2014).  Lee et al. (2011) 
suggested the missing heritability may be a result of small effect sizes that fail to reach GWAS 
significance levels, which complements Duerr.   Lee et al. (2011) also suggests that causal variants 
may be missed due to lack of association caused by insufficient LD with SNPs on commercial 
arrays. In conclusion Lee et al. (2011) suspects a proportion of heritability will always be missing 
as a result of rare casual variants of small effect.  
Between 2008 and 2013, 38 Genome Wide Association studies submitted to the 
Genome.gov database, have investigated the genetic component of IBD, CD or UC.  The findings 
of these studies have reinforced the theory that IBD is a non-Mendelian, multifactorial disease 
requiring environmental trigger(s) to initiate the onset in a genetically susceptible host.  
GWAS studies have aided in making significant progress towards identifying the 
pathogenesis of IBD.  The genes identified through GWAS are linked to at least 7 different 
pathways, however how dysregulation of gene function and ultimately disruption in these 
pathways causes the IBD phenotype is still unclear (Dinwiddie et al. 2013). 
When one combines the following factors: an increase in incidence of disease worldwide, 
an increasing burden of disease, an unknown etiology and unidentified heritability, it becomes 
quiet clear, IBD is quickly emerging as a major world public health concern.   
This literature review first aims to bring together the most current epidemiological and 
clinical information pertaining to IBD, specifically Crohn’s Disease and Ulcerative Colitis.  A 
second aim is to gather information on environmental risk factors and other influences associated 
with IBD.  A third aim of this review is to discuss the previous genetic research and what 
information has been gleaned from those studies.  And the final aim of this paper is to summarize 
this information as it pertains to genetic counseling.     
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2.0  INFLAMMATORY BOWEL DISEASE 
Inflammatory Bowel Disease (IBD) is a chronic inflammation of the gastrointestinal tract with 
recurring periods of relapse and remission.  Periods of relapse, known as flares, can be mild to 
severe and intermittent or chronic.  Currently there is no known pathogenesis, etiology or cure.  
The majority of IBD cases can be divided into two major sub classifications: Ulcerative 
Colitis (UC) and Crohn’s Disease (CD).  There is also a third class of IBD called “indeterminate 
colitis” (IC) which represents about 10-15% of affected individuals (Sura et al. 2014).  Rare forms 
of IBD include collagenous colitis, lymphocytic colitis, diversion colitis, and Behcet’s disease; 
however, these will not be discussed in this paper. 
It is medically necessary to appropriately diagnosis a patient for the purposes of effective 
medical management.  For example, in severe cases where surgery is required, an ileal pouch-anal 
anastomosis is contraindicated when the diagnosis is CD (Geoboes et al. 2008).  Early use of 
biologics is recommended to reduce the complications of CD, but is not the case for UC  (Sura et 
al. 2014). 
In the following sections we will discuss the clinical manifestations, histological 
presentation, and unique characteristics of CD, UC, IC, as well as childhood and adolescent onset 
forms of IBD. 
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2.1.1 Crohn’s Disease (CD) 
2.1.1.1 Clinical Features 
Crohn’s Disease (CD) is clinically recognized by the following symptoms: persistent diarrhea, 
rectal bleeding, urgent need to move bowels, abdominal cramps and pain, sensations of incomplete 
evacuation (tenesmus) and constipation, which can lead to bowel obstruction.  Individuals with 
CD can also experience complications such as: abscesses, fistulas and strictures (Zhang and Li 
2014).  Fatigue, loss of appetite, weight loss, night sweats, and for women loss of a normal 
menstrual cycle are all common outward signs of disease (CCFA 2014).  Almost 50% of 
individuals with CD experience extraintestinal manifestations such as: arthritis, uveitis, and 
erythema nodosum. Onset can occur at any age; however, it usually occurs between the ages of 
15-30 years old (Laass et al. 2014). 
2.1.1.2 Histology 
CD can affect any part of the GI tract from the mouth to the anus and the inflammation commonly 
presents in a discontinuous fashion; where patches of the GI tract appear normal in between areas 
of severe inflammation (Laass et al. 2014).The common histological features are: non-cryptolytic 
granulomas, focal or patchy lamina proprial chronic inflammation, focal or anatomically 
discontinuous crypt distortion, ileal involvement, absence of features of ulcerative colitis, 
decreasing proximal to distal gradient of changes, and a normal mucosal surface (Feakins 2014; 
Margo et al. 2013). 
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2.1.1.3 Therapy 
Treatments for CD can include: antibiotics, aminosalicylates, corticosteroids, immunomodulators, 
anti-TNF-antibodies and other novel biological drugs.  Treatment choice is usually based of 
disease severity, location, and behavior and whether or not surgery is being considered or has 
already been performed. Exclusive enteral nutrition is recommended in children with acute disease 
as it provides the greatest gains for weight and growth with the least amount of side effects (Laass 
et al. 2014). 
2.1.2 Ulcerative Colitis (UC) 
UC can be further disseminated in to 3 sub categories based on location/extent of inflammation.  
First is proctitis: inflammation is limited to the rectum, second is left-sided colitis: inflammation 
extends from the rectum to splenic flexure, and third is pan-colitis: inflammation of the entire 
colon.  
Table 2. is a modified table taken from Conrad et al. (2014) which presents the prevalence 
of some of the more common signs and symptoms of UC that can occur.   
Table 2. Distribution of Signs and Symptoms in Adult Onset Ulcerative Colitis 
Signs and Symptoms Prevalence in Adult onset UC 
Diarrhea 70 – 90% 
Abdominal Pain 30 – 70% 
Weight Loss 35 – 45% 
Rectal Bleeding 50 – 90% 
Extraintestinal Manifestations 2 – 15% 
 
 
. 
The data for this table was adapted from Conrad et al. (2014) and represents the 
prevalence of specific symptoms at the onset of UC in adult patients. 
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2.1.2.1 Clinical Features 
The physical symptoms of UC consist of: blood in the stool, increased bowel movement frequency, 
tenesmus, diarrhea, and abdominal pain (Ordas et al. 2012; Conrad et al. 2014). Individuals with 
UC may also experience: fatigue, loss of appetite, weight loss, night sweats, and for women loss 
of a normal menstrual cycle (CCFA 2014).  
While most likely an underestimation, at least 1/3 of individuals with IBD have some type 
of extra intestinal manifestation.   These include but are not limited to: arthritis, uveitis 
(inflammation of the covering of the eye), skin lesions and sacroilitis (inflammation of the large 
joints of the tail bone and pelvis) (Cummings and Rubin 2006). 
Individuals with UC can commonly have other manifestations of disease such as 
inflammatory arthropathies and primary sclerosing cholangitis (PSC), which are the most 
common.   PSC, an inflammation of the ducts of the liver occurs in about 2-10% of patients and 
occurs independent of IBD.   Other extraintestinal manifestations include: erythema   nodosum, 
pyoderma gangrenosum, episcleritis, uveitis and osteoporosis (Conrad et al. 2014; Cummings and 
Rubin 2006). 
The onset of UC can occur at any age; however, the majority of individuals with UC will 
typically present between the ages of 15-30 years, with a smaller major group presenting between 
the ages of 50-70 years (Ordas et al. 2012; Hanauer  2006).  
2.1.2.2 Histology 
UC is distinct from CD in that the inflammation is contained to the mucosal surface and found 
only in the colon, always including the rectum, with a few exceptions.  Conrad et al. (2014) states 
that nonspecific mucosal inflammation in the terminal ileum or “backwash ileitis” occurs in 10–
 12 
20% of UC patients and rectal sparing may  occur  in 30% of untreated children, 13% of adults 
with fulminant colitis or 44% of patients receiving topical or systemic treatment.   
UC is characterized by its continuous pattern of inflammation along the epithelial lining 
with a visibly sharp transition from inflamed and normal mucosa, neutrophilic mucosal infiltrate, 
goblet cell depletion, ‘cryptitis’ and prominent crypt abscesses (Thompson and Lees 2011). 
2.1.2.3 Therapy 
In cases of mild to moderate UC, topical or oral aminosalicylates are used, e.g. mesalamine or 
sulfasalazine.  Topical is most often used for patients with proctitis or left sided colitis.   For 
individuals with moderate to severe disease that shows no response to aminosalicylates, steroids 
are the next approach, commonly prednisolone or an equivalent (Conrad et al. 2014). 
In more severe cases where the individual is chronic and/or steroid dependent, 
immunosuppressive treatment is recommended with azathioprine or 6-mercaptopurine. Anti-TNF-
alpha antibodies may be an option to induce and maintain remission in patients with steroid 
refractory or dependent disease (Conrad et al. 2014).  A common surgical treatment is total 
proctocolectomy with ileal pouch-anal anastomosis, which may be required in patients with 
longstanding disease, in fulminant colitis, or in the prevention of colon cancer (Conrad et al. 2014).   
2.1.3 Indeterminate Colitis 
For some patients, approximately 10-15%, it can be difficult to give a diagnosis of UC or CD (Sura 
et al. 2014). An accurate diagnosis is critical for appropriate medical management as some 
therapies for the treatment of UC are contraindicated for CD and vice versa.   
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For individuals who clearly present with symptoms of IBD, but have ambiguous 
histological findings, they are given a temporary diagnosis of indeterminate colitis (IC)  (Geoboes 
et al. 2008; Margo et al. 2013).  Indeterminate colitis (IC) has also been described in the literatures 
as “uncertain colitis”, “inflammatory bowel disease unclassified (IBDU)”, “CIBD-unclassified” 
and “chronic idiopathic inflammatory bowel disease NOS” (not otherwise specified)  (Margo et 
al. 2013). 
2.1.3.1 Clinical Features 
There are no exact clinical features for IC, other than an incongruent mix of CD and UC symptoms 
and histology.   It is thought that a case presenting as IC may in fact be the early stages of UC, as 
most of these cases behave similar to UC and are later reclassified (Geoboes et al. 2008).  IC is 
often the case in children, about 23% of new onset cases, particularly in those > 12 years old  
(Margo et al. 2013).  
2.1.3.2 Histology 
The characteristic histology of an individual with IC is extensive ulcerations with involvement of 
transverse and right colon, with the appearance of diffuse disease (Margo et al. 2013). Both severe 
mucosal and wall involvement is seen with non-aggregated transmural inflammation.  There is 
often a discontinuous pattern with fissures reaching the muscularis propria and sharp transitions 
from ulcerated areas to adjacent normal mucosa (Margo et al. 2013).  
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2.1.4 Genetic Counseling Take Away Points 
• The average age of onset for IBD is between 15 – 30 years old 
• CD 
o Inflammation can affect any part of the GI tract and occurs in patches and 
penetrates deep into the epithelial layers.  
o Fistulas, strictures, and abscesses are common complications 
• UC 
o Inflammation almost always includes the rectum and is usually confined to 
the colon with a few cases of ileum involvement.  
o Inflammation occurs in a continuous fashion along the mucosal surface.  
• IC 
o 10-15% of IBD cases are considered “indeterminate” 
o Histological findings are an incongruent mix of both CD and UC features 
o It is important that other causes of inflammation such as bacterial infection 
are ruled out before the diagnosis is given 
o Correct diagnosis is important for proper medical management 
2.2 CHILDHOOD AND ADOLESCENT IBD 
Twenty-five percent of individuals with IBD are children or adolescents (Levine et al. 2011; Laass 
et al. 2014).  And 20 to 30% have onset of symptoms before the age of 18, with diagnosis often 
occurring later (Conrad et al. 2014).  2% of diagnoses are in children less than 10 years old 
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(Cummings and Rubin 2006). CD tends to be more prevalent in pediatric cases compared to adult 
cases, which have higher rates of UC (Ruel et al. 2014). 
Childhood onset can be further classified into 3 sub groups based on age at diagnosis: 
Infantile onset, diagnosis prior to age 1; Very early onset (VEO-IBD), diagnosis prior to age 6; 
and Early onset (EO-IBD), diagnosis prior to age 18 (Dinwiddie et al. 2013).  
 An interesting finding that separates childhood onset from adult cases is the clinical 
presentation of disease.  Knights et al. (2013) explains that between the ages of 0 to 2 presentation 
is atypical with CD cases having affected colons and UC cases presenting with pancolitis (Knights 
et al. 2013).  Another atypical finding mentioned by Laass et al. (2014) is that in adult onset CD, 
disease localization usually remains constant within the first year, however in 40% of children 
with CD the disease extends within the GI tract within the first 2 years of onset   (Laass et al. 
2014). 
Table 3. Adult vs. Childhood Onset of Ulcerative Colitis 
UC Classification Prevalence in 
Adult onset 
Prevalence in 
Childhood onset 
Proctiitis 40 - 50 % 1.4% 
Left-sided Colitis 30 - 40% 16% 
Pancolitis 25 - 30% 82% 
 
 
 
 
 
 
Graham and Xavier (2013) suggest that because we see both pediatric and adult cases of 
IBD, distinct environmental influences must exist that contribute to disease initiation rather than 
disease progression (Graham and Xavier 2013).  However, research has uncovered age specific 
mutations, which in cases of VEO-IBD, are believed to play a more pivotal role.  A few of the 
genes associated with early onset are: NOD2, IL-10RA, IL10-RB, IL-10, XIAP, ADAM17, 
The information in this table was adapted from Conrad et al. (2014) and presents the difference in the 
percentage of cases that occur in each sub category of ulcerative colitis based on age of onset. 
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NCF2/RAC2 and NCF4, TNFRSF6B, PSMG1, SLC22A4/5 and an early-onset IBD panel, 
consisting of over 30 genes, is offered by Emory Laboratories.  IBD researchers question whether 
an increased load of susceptibility genes or mutations in specific genes are what separates adult 
from childhood onset IBD.  Evidence supporting the specific gene theory is the case of autosomal 
recessive loss of function mutations in IL-10 receptor (IL10RA and IL10RB) subunit genes, which 
have been documented to cause a severe CD phenotype without any apparent environmental 
triggers (Rogler 2011; Thompson and Lees 2011; Dinwiddie et al. 2013; Ruel 2014). 
2.2.1 Genetic Counseling Take Away Points 
• CD is more common in male children. 
• Symptoms and disease progression are different between adult and pediatric cases 
with the majority of pediatric cases of UC diagnosed as pancolitis and the majority 
of CD cases diagnosed with colonic inflammation. 
• Current research suggests that there is a greater genetic effect in childhood onset 
cases.  Emory laboratories offers a panel for early onset cases. 
2.3 SEX EFFECT 
Kappelman et al. (2013) study of commercially insured Americans below the age of 65 found sex 
differences were only significant for CD. Conrad et al. (2014) also discusses a lack of significant 
differences in the appearance of UC between males and females.   
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Ruel et al. (2014) questioned whether the age of onset affected the male to female ratio of 
disease.  The study found UC pediatric cases are about equal in the distribution of disease between 
males and females, however, adult onset cases tend to have a higher female prevalence of UC. 
Typically there are more males affected with CD in pediatric cases compared to adult cases where 
females with CD are more prevalent.  This change in distribution appears to occur between the 
ages of 14-17 years, usually soon after puberty.  This shift has also been seen in type 1 Diabetes, 
other immune-mediated inflammatory disease.  It’s possible a change in hormones may play a role 
in disease pathogenesis.  
In Nguyen et al. (2006) study of racial and ethnic differences among adult IBD cases, and 
found AA females to have a slight predominance compared to females of the white and Hispanic 
cohorts, 63% to 51% and 45%, respectively.   
2.4 INCIDENCE AND PREVALENCE  
2.4.1 USA  
According to the Centers for Disease Control (CDC) website, accessed in April of 2014, the current 
estimated prevalence of IBD in the USA is 1.4 million people.  The CDC also estimates the 
incidence rates of IBD worldwide as follows: UC: .5 – 24.5 / 100,000 persons and CD: .1 – 16 / 
100,000 persons. 
Kappelman et al. (2013) utilized the 2009 US census data to estimate the prevalence of CD 
and UC for the USA.  The investigators standardized the data for age, gender and region, 
estimating roughly 1,171,000 Americans have IBD with an approximately equal split between UC 
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Data for this table was taken from Molodecky et al. 2012 and represents the known incidence rates of IBD as of 2009 in 
Europe, Asia/Middle East, and North America and the prevalence rates of IBD in Europe and North America as of 2009.  
 
and CD (593,000 UC and 565,000 CD).   Of those affected roughly 5% or 62,000 were pediatric 
cases under the age of 20 years. (23,000 UC and 38,000 CD). The value of this data is limited as 
it only captures individuals who had commercial insurance and were younger than 65 years old. 
Because of this limitation the numbers are most likely an underestimate of true disease prevalence 
in the USA today. 
2.4.2 Worldwide 
Dinwiddie et al. (2013) reported that 2.5 million people worldwide have IBD.  Molodecky et al. 
(2012) used a systematic review to establish changes in the incidence and prevalence rates of IBD 
worldwide analyzing 246 studies between 1950-2010.  Their findings are provided in Table 4.   
Table 4. Incidence and Prevalence Rates for IBD Worldwide 
Incidence    
 Europe North America Asia and Middle East 
UC 24.3 per 100,000 persons 19.2 per 100,000 persons 6.3 per 100,000 persons 
CD 12.7 per 100,000 persons 20.2 per 100,000 persons 5.0 per 100,000 persons 
    
Prevalence    
 Europe North America Asia and Middle East 
UC 505 per 100,000 persons 249 per 100,000 persons N/A 
    
CD 322 per 100,000 persons 319 per 100,000 persons N/A 
 
 
 
After a time-trend analysis Molodecky et al. (2012) found that in CD vs. UC studies 
incidence rates increased with a statistical significance of 75% vs 60% respectively. Overall they 
concluded that IBD is an emerging global disease and more epidemiological data is needed to 
show accurate incidence and prevalence data across the globe.  
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3.0  ENVIRONMENTAL INFLUENCE AND RISK FACTORS 
3.1 “WESTERNIZATION” THEORY  
The “Westernization Theory” is an intriguing trend emerging in the worldwide epidemiology of 
IBD postulating that certain lifestyle changes and environmental exposures could put 
“westernized” individuals at greater risk for developing IBD.    
The theory is based on the rate of increasing occurrence of UC and CD in parts of the world 
where previously it was very rare (i.e. Asia, Japan, Africa, and the Middle East) with the highest 
rates of growing incidence occurring in the developing or industrializing regions of these countries 
(Molodecky et al. 2012; Chen et al. 2014).   As a result of these once rural populations becoming 
urbanized, there is a tendency to develop a more “Westernized lifestyle”, which constitutes a 
higher socioeconomic status, an increase in stress, an increase in smoking, a change of diet to one 
higher in sugar, fat, and processed foods as well as greater access to medications such as antibiotics 
and NSAIDs  (Ananthakrishnan 2013). 
Additionally, in urban settings not only is access to medications more likely, but access to 
physicians aware of diseases such as UC and CD increases, resulting in a increased UC and CD 
diagnosis reporting in medical records (Molodecky et al. 2012; Chen et al. 2014; Danese and 
Fiocchi 2011; Ordas et al. 2012). In addition to the individualized or societal environmental 
factors, industrialization affected environmental factors such as increasing levels of atmospheric 
air pollution; specifically high levels of NO2 and SO2 have been shown to correlate to an increased 
risk of CD and UC (Zhang and Li 2014). 
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3.2 HYGIENE HYPOTHESIS  
Along with a more westernized lifestyle individuals living in cities often live a more sanitary 
existence as well.  The “hygiene hypothesis” postulates that reduced exposure to enteric infections 
during childhood inhibits the maturation of the mucosal immune system, which subsequently puts 
them at risk for inappropriate response to pathogens later in life (Ordas et al. 2012).   Additional 
risk factors associated with this hypothesis are: helminthic infections and antibiotic use during 
childhood; breastfeeding; family size and/or sibship; urban vs. rural lifestyle; and personal and 
domestic hygiene in childhood. 
Helminths are parasitic worms transmitted through soil contaminated with human feces 
harboring the worm eggs.  Ruel et al. (2014) discusses that exposure to helminthes induces a strong 
type 2 T helper cell (TH2) and regulatory T cell (TREG) response.  An exaggerated TH2 response 
is what is believed to drive the aberrant inflammation seen in UC.  Also the TH2/TREG response 
is believed to oppose the type 1 T helper cell (TH1) response associated with CD (Ruel et al. 2014; 
Ordas et al. 2012).    According to this evidence perhaps, a lack of exposure to this type of parasite 
early in life leaves the immune system ill practiced in these pathways, so that later in life, when 
these pathways are activated by some other trigger, the immune system responds more robustly.      
3.3 IMMIGRATION EFFECT 
Additionally, improved hygiene might be linked to an “Immigration Effect”.  Several studies have 
found that there is an increased risk to individuals and their offspring who emigrate from areas of 
low IBD prevalence to areas of high IBD prevalence. Cummings and Rubin (2006) cited a 1999 
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study that stated when populations move from low risk areas, i.e. rural settings, to higher risk areas, 
i.e. developing cities, the incidence of IBD increases in those populations.  Conrad et al. (2014) 
cited a similar finding and attempted to link the increased risk back to the hygiene hypothesis, 
suggesting that certain exposures during infancy/early childhood are involved in the development 
of IBD, specifically the risk for UC (Chen et al. 2014; Conrad et al. 2014). 
3.4 CIGARETTE SMOKING 
One of the most well studied risk factors is cigarette smoking. Studies have shown a 2 fold 
increased risk for development of CD in individuals who smoke.  However, smoking appears to 
be a protective factor against the development of UC. It has also been observed that when cessation 
of smoking occurs the protective factor also ceases and individuals will see an increase in disease 
activity. A meta-analysis, cited by Ordas et al. (2012) showed that smoking is protective against 
ulcerative colitis compared with non-smoking  (odds ratio  [OR] 0·58, 95% CI 0·45–0·75) (Ordas 
et al. 2012; Zhang and Li 2014).  Nguyen et al. (2006) also found the role of smoking to be 
consistent between Hispanic and white cohorts stating in their results that the Hispanic UC patients 
had higher rates of nonsmoking at time of diagnosis associated with more extensive disease and 
higher rates of colectomy.  
Ananthakrishnan (2013) proposes that smoking, in connection to the composition of the 
microbiome, has modifying effects on the intestinal immune response possibly caused by free 
radical-mediated oxidative stress.  However, researches and doctors do not promote smoking as a 
condoned behavior to reduce the risk of UC.    
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3.5 APPENDECTOMY 
Appendectomy is another well-investigated risk factor that appears to reduce the risk of developing 
UC.  Appendectomies that occur before the age of 20 have been shown to reduce the risk of 
developing UC by 69% (Ordas et al. 2012).   However, it has not been shown to be protective 
against the development of CD.  Whether this association is of a true causality is still yet to be 
established (Ananthakrishnan 2013).  
3.6 VITAMIN D 
Data is emerging that links vitamin D to having immunological functions within the innate and 
adaptive immune system, as well as, playing a role in various autoimmune and inflammatory 
diseases (Yin and Agrawal 2014; Zhang and Li 2014).  Yin and Agrawal (2014) explain that 
vitamin D plays a role in mucosal barrier homeostasis, which is a critical component of IBD 
development.  vitamin D has been seen to be associated with preservation of epithelia cell junction 
integrity, which aids in the proper regulation of the immune/inflammatory response, by reducing 
the risk of pathogen infiltration this in turn, reduces the risk of mucosal damage and IBD (Yin and 
Agrawal 2014).   
Studies have shown a high prevalence of vitamin D deficiency in patients with IBD, (16–
95% according to Mouli and Ananthakrishnan (2014)) and found that supplementation of vitamin 
D, specifically D3, has a significant effect on the activity of IBD. Mouse models have shown 
increased levels of colonic inflammatory cytokines in vitamin D receptor knockout mice. 
However, genetic association studies are still inconclusive and larger randomized studies are still 
 23 
needed to prove its effectiveness as a potential treatment (Yin and Agrawal 2014; Ananthakrishnan 
2013; Mouli and Ananthakrishnan 2014).  
Wang et al. (2014) performed a meta-analysis of research that investigated four 
polymorphisms of the vitamin D receptor gene, VDR, and its connection to IBD. The 
polymorphisms were labeled by the restriction enzymes: ApaI  (rs7975232), TaqI (rs731236), and 
BsmI (rs1544410) and FokI (rs10735810).  They concluded that in Caucasians especially, ApaI 
polymorphism may increase the risk of CD, and TaqI polymorphism may decrease the risk of UC.  
3.7 MICROBIOME 
The number of catalogued bacteria within the human gut current stands at roughly 1150 different 
bacterial species. However, each individual person hosts roughly 160 different bacterial species 
(Zhang and Li 2014).  This suggests that not every human gut microbiome is the same and different 
permutations of bacteria may have varying affects on health.  IBD researchers are now 
investigating whether particular compositions of bacterial species play a role in who does and does 
not develop IBD.  Another question is whether or not certain environmental exposures can alter 
the microbiome from “homeostasis” to dysbiosis that triggers the immune response seen in IBD 
patients (Knights et al 2013).    
3.7.1 Antibiotics 
Use of antibiotics can upset the natural equilibrium of the microbiome by eliminating pathogenic 
and commensal bacteria, leaving the gut susceptible to an over abundance of certain types of 
 24 
bacteria.  Kostic et al. (2014) puts forth the idea of “colonization resistance” one of the many ways 
commensal bacteria keeps its end of the symbiotic bargain. Commensal bacteria occupy a 
sufficient amount of the gut surface area leaving pathogenic bacteria unable to find a “niche” in 
which to colonize and overwhelm the host. If this theory is true, a round of broad-spectrum 
antibiotics could make an individual susceptible to colonization of unwanted bacteria (Kostic et 
al. 2014).  Reduced levels of beneficial bacteria such as: as Bifidobacterium, Lactobacillus, 
Bacteroidetes and Firmicutes along with increased levels of less helpful bacteria such as 
Enterobacteriaceae and Fusobacterium spp. have been found in individuals with IBD (Zhang and 
Li 2014). More specifically Enterobacteriaceae and pathogenic bacteria that promote inflammation 
are increased in patients with Crohn’s disease and Escherichia coli are increased in patients with 
UC (Ruel et al. 2014; Zhang and Li 2014).  Pediatric cases appear to have increased levels of 
aerobic and facultative-anaerobic bacteria, whereas adult IBD is associated with an increase in 
numbers of anaerobic bacteria (Ruel et al. 2014).  
3.7.2 Bacterial Infections 
Both Ordas et al. (2012) and Ananthakrishnan (2013) agree that episodes of prior gastrointestinal 
infections may lead to chronic IBD, going on to explain that exposures, in a genetically susceptible 
host, may change the gut flora enough to trigger the chronic inflammatory response that is IBD. 
Ordas et al. (2012) discusses specific exposures to Salmonella, Shigella, and Campylobacter 
bacteria, doubles the risk for the development of UC. And Ananthakrishnan (2013) discusses that 
the infection risk is bidirectional; infections prior to disease onset may be a trigger that aids the 
onset of disease; and then post IBD onset, the individual then becomes susceptible to enteric 
infections, particularly Clostridium difficile.  
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In 2013, A.N. Ananthakrishnan, gives an interesting commentary, in the Journal of 
Pediatrics, on a paper written by Kronman et al. in 2012 called “Antibiotic exposure and IBD 
development among children: a population-based cohort study”.   The authors concluded that, in 
childhood, antianerobic antibiotic exposure is associated with IBD development. 
Ananthakrishnan’s commentary expresses that because a bacterial infection is often tied to 
exposure to antibiotics it is difficult to determine which exposure is linked to the underlying 
etiology of IBD. However, Ananthakrishnan (2013) agrees that the literature strongly supports 
antibiotic exposure and IBD risk.  While the risk is low it should still bring physicians to pause 
before prescribing antibiotics at an early age.  
3.7.3 Breastfeeding 
The microbiome of the gut develops soon after birth and historically a child’s first exposure to 
food outside the womb was breast milk.  With the advent of baby formula many children are never 
exposed to breast milk leading researchers to question whether a link exists between breastfeeding 
and IBD development (Ruel et al. 2014). Specifically with UC, Ordas et al. (2012) states 
breastfeeding is protective when the duration is for more than 3 months.  Ruel et al. (2014) 
discusses the difference in bacterial diversity between breastfed and formula fed babies, stating 
breastfed babies have mostly helpful bacteria while formula fed babies have a more diverse 
bacterial load that includes more pathogenic types.  The extent that formula or breast milk effects 
risk requires further investigation. 
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3.7.4 Microbiome integrity and age 
The biodiversity of the gut goes through age specific transitions which correlate to the 3 peak 
periods of disease onset: early onset occurring <10 years, peak onset 15 – 30 years, and elderly or 
late onset occurring >60 years. The microbiota of the gut alters its diversity and is unstable during 
these transitions.  After birth the microbiome does not reach full stability and strong diversity until 
adulthood.  It is influenced by type of delivery, vaginal or C-section, diet, breast milk or formula, 
and then again when a switch to solid foods is made.  The stability of the bacteria of the gut is also 
influenced by illness and puberty.     Stability is often maintained until after the age of 60 where 
the microbiome is more susceptible to fluctuations and distress (Kostic et al. 2014; Ruel et al. 
2014).  The immune system also differs as we age.  In the elderly, immunosenescence occurs 
resulting in increased risk for infection and autoimmunity to occur.  Age is an integral component 
in identifying the degree to which certain factors contribute to the onset of IBD.  Figure 1. 
demonstrates how the effects of genetics appear to have a stronger influence earlier in life, 
conversely environmental influences appear to have a greater impact on IBD development in the 
elderly.  
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The above figure was adapted from Ruel, J. et al. (2014) and demonstrates the differing affects of factors contributing 
to IBD over the lifetime.   
Figure 1. Affects of Age on IBD  
This figure also demonstrates how genetics plays a greater role in the development of 
childhood IBD.  Recessive IL-10RA and IL-10RB loss of function mutations are capable of 
causing early onset Crohn’s phenotype without an environmental trigger (Ruel et al. 2014; 
Dinwiddie et al. 2013). 
3.8 MEDICATIONS 
Other types of medications have been studied as possible disease modifiers.   Research on NSAIDs 
usage has been shown to disrupt the integrity of the intestinal mucosal barrier, which can make the 
gut lining more susceptibility to pathogenic bacteria, in turn potentially igniting an inflammatory 
Influence of Genetics 
    Influence of Environment  
and Gut Microbiota 
Early onset 
<10 yrs 
Peak onset 
15 -30 yrs 
Late onset 
>60 yrs 
Alterations in the innate and 
adaptive immune systems  
with ageing 
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response (Ruel et al. 2014). And if the NSAID user also has genetic susceptibility to IBD they are 
at an increased risk for a dysregulated response.  While there have been several studies that show 
exposure to antibiotics and NSAIDs are increased in individuals who later develop IBD, the exact 
risk still needs to be validated (Ananthakrishnan 2013; Ordas et al. 2012; Zhang and Li 2014). 
3.9 HORMONAL INFLUENCE 
Researchers have also questioned whether there is a hormonal influence associated with onset of 
IBD.  Studies have shown elevated risks for the development of IBD in women who use oral 
contraceptives as well as women who have endometriosis. (Ananthakrishnan 2013 10; Ordas et al. 
2012 ).   
3.10 PSYCHOLOGICAL STRESS, ANXIETY AND DEPRESSION 
While Ordas et al. (2012) did not find any data to support the role of psychological stress on the 
development of UC, Ananthakrishnan (2013) discusses that psychological changes can have an 
effect of the autonomic and sympathetic nervous system, which can be influential in the activation 
of the immune system.  Rogler (2011) explains that while stress does not directly cause the 
manifestations of IBD it acts as a disease modulator.  However, there is no strong human data to 
rule in or rule out the etiological role of an individual’s mental state and the development of IBD 
(Zhang and Li 2014).   
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3.11 DIET 
Diet is certainly on the list of factors that need be more heavily investigated; however, prospective 
and even retrospective case / control studies are very difficult to perform and even more difficult 
to infer causality.  Most often diet studies require patient journaling and backfilling is a common 
occurrence, which limits the integrity of the results.   However, as Ananthakrishnan (2013) 
explains patients commonly inquire about dietary options that may reduce symptoms without the 
cost and side effects of pharmaceuticals.  
Studies have attempted to find a connection between diet and disease, by examining the 
pre-illness diet of those with IBD.  Common trends seen in IBD diet studies are a reduction of 
fiber specifically soluble fiber from fruits and vegetables and an increased intake in high fat in 
individuals with IBD (Ananthakrishnan 2013).  Specific types of fats were found to have varying 
affects on IBD and that information is provided in Table 5. below.   
Table 5. Dietary Components as Potential Risk Factors 
 
 
Knights et al. (2013) suggests that long-term dietary habits can affect the gut microbiome 
and that shifts in particular nutrients, such as sulfur and tryptophan could start a chain of events 
that ends in the triggering of an inflammatory response.   Graham and Xavier (2013) also suggest 
tryptophan as well as dietary levels of salt can be upstream triggers of the inflammatory response.  
 Arachidonic 
acid 
Linoleic  
acid 
Dietary n-3  
polyunsaturated 
fatty acid 
Docosahexaenoic 
acid 
Carbohydrates Soluble 
fiber 
Animal 
Protein 
Risk of UC Increased Increased Protective Protective Inconsistent N/A N/A 
Risk of CD N/A N/A N/A N/A Inconsistent Protective Increased 
The above table was created using data from Ananthakrishnan, A.N. (2013). This table presents the differing affects 
certain foods have on IBD phenotype. 
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However, survey data suggests food triggers amongst IBD patients are not universal and it 
has been proposed that particular triggers may be linked to specific genotypes.  Rigorous studies 
are still needed to validate the utilization of diet as a therapy option (Ananthakrishnan 2013).   
3.12 GENETIC COUNSELING TAKE AWAY POINTS 
• Westernization Theory / Hygiene Hypothesis: There appears to be a correlation between 
IBD and living a “westernized lifestyle. 
• Cigarette Smoking: Studies have shown smoking is a protective factor in cases of UC but 
increases the risk of CD.   
• Appendectomy: Studies have shown appendectomy is a protective factor in cases of UC 
but does not have an effect on CD 
• Vitamin D: Vitamin D deficiency appears to be associated with IBD and vitamin D 
supplementation may be a possible adjunct therapy 
• Microbiome: The integrity of gut bacteria is a major area of investigation.  The exact factors 
(i.e. bacterial infections, antibiotics, NSAIDs, hormones, age) that change the gut bacteria 
and exactly what that change looks like are still being elucidated.   
• Stress: Stress may act as a disease modulator affecting disease symptoms but not disease 
onset.  
• Diet: No clear-cut associations between diet and disease have been validated. 
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4.0   GENETIC RESEARCH IN INFLAMMTORY BOWEL DISEASE 
“IBD is a complex genetic disorder characterized by non-Mendelian inheritance, in complete 
penetrance and disease susceptibility but not disease certainty” (Konda et al. 2006). 
4.1 FAMILY STUDIES 
A landmark article in IBD family history research is the Orholm et al. (1991) paper; which reported 
that a 10-fold increase in familial risk strongly suggests a genetic cause.   His study surveyed 637 
patients with IBD in the county of Copenhagen, Denmark.  These individuals were followed for 9 
years to determine the rates at which their relatives developed IBD.  The study findings are 
represented in Table 6. below. 
 
Table 6.  First-Degree Relative Risk for Developing IBD 
 Risk for 1st degree relative to 
develop UC 
Risk for 1st degree relative to 
develop CD 
Proband has UC 9.5 fold greater 1.8 fold greater 
Proband has CD 4.4 fold greater 10.3 fold greater 
 
 
The above table was created using data from Orholm et al. (1991) and demonstrates the greater risk to develop the 
same disease type as first degree family members and that CD appears to confer the greatest overall risk.  
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Orholm et al. (1993) utilized the same data to analyze the mode of inheritance through 
complex segregation analysis, concluding there is a dominant gene in effect in 10% of UC patients, 
and in 7% of CD patients there is a recessive gene at play.   
Russell and Satsangi (2004) explains in “IBD: A Family Affair”, that the risk is highest for 
siblings of a CD proband and may be as great as 1 in 3 but that in general first-degree relatives of 
a proband with IBD have a 1 in 10-20 risk (Russell and Satsangi 2004).  Ruel et al. (2014) discusses 
that there appears to be a greater prevalence of positive family history in cases of pediatric onset, 
suggesting genetic factors may play a more substantial role in these cases.   
4.1.1 Anticipation 
Researchers began to investigate the possibility of anticipation as a cause for familial IBD when 
studies showed children of IBD affected parents often had an earlier age of onset.  Earlier studies 
supported the existence of anticipation (Grandbastien et al. 1998; Lee and Lennard Jones 1996; 
Polito et al. 1996; Satsangi et al. 1998); however, more recent studies have found evidence that 
suggests anticipation is most likely an artifact of methodological biases.   
Peeters et al. (2000) discusses several interesting points that may create the appearance of 
anticipation; first both parents and medical professionals are more aware of the signs and 
symptoms of IBD which may aid in earlier diagnosis also with each generation diagnostic accuracy 
improves.   Methodological biases are also discussed; such as recall bias and preferential 
ascertainment of later onset parents leading to selection or truncation bias and finally inadequate 
follow-up may all contribute to the manifestation of anticipation.  
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A German study published in the year 2000 investigated the likelihood of anticipation in 
IBD.   The study population consisted of 2,007 IBD patients with sporadic disease and 472 
multiplex familial cases (including 103 affected parents and 99 children of affected patients).    The 
results of the study found that the mean-age-of onset in children was 19.4 years earlier than their 
affected parent.  When the investigators corrected for the confounding variables of higher age of 
the parental cohort and longer diagnostic interval in a general linear model there was no significant 
difference and no apparent anticipation (P≥0.52).  The authors stipulate that ascertainment bias is 
the most likely explanation for the presentation of anticipation in the raw data and go on to state 
that the power to detect true anticipation in a complex disorder is quite low and conclude that the 
results of this study provide further evidence that anticipation in IBD does not occur (Hampe et al. 
2000).    
Russell and Satsangi (2004) reported evidence of a strong concordance between disease 
type and location in twin and multiplex family studies. However, stating that even though more 
than 75% of children with IBD were diagnosed younger than their IBD parent(s) the possibility of 
true genetic anticipation was unlikely. 
 
4.1.2 Ethnicity 
4.1.2.1 Ashkenazi Jews  
Yang et al. (1993) investigated the potential ethnic predilection of IBD in individuals of Jewish 
decent.  The results of that study concluded that the lifetime risk to develop IBD in first-degree 
relatives of non-Jewish probands who had UC was 1.6% or probands who had CD 5.2%.  First-
degree relatives of UC Jewish probands had a lifetime risk to develop IBD of 4.5% and 7.8% when 
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the proband had CD. (p value for comparison between Jews and non Jews: 0.028; between UC and 
CD: 0.005).   Yang et al. (1993) goes on to explain that the differing risk values support the theory 
that IBD does not fit a single Mendelian gene model.  
While IBD may not be a Mendelian disorder, evidence still supports the existence of a 
genetic component.  Ordas et al. (2012) explains that overall individuals of Ashkenazi Jewish 
decent have a rate of UC 3 to 5 times that of other ethnicities and Yang et al. (1993) showed that 
incidence and prevalence was consistent when compared to other ethnic groups in the same 
location, and the consistency was perpetuated over different time periods and geographical 
locations.  
4.1.2.2 African American and Hispanic  
Nguyen et al. (2006) published research investigating the racial implications in adult IBD.  The 
study consisted of 1,126 subjects: 830 White, 127 African American (AA), and 169 Hispanic.  This 
large study allowed for significant power to detect any racial differences that may exist. 
They found that the distribution of disease subtype, UC or CD, was consistent across all 
groups with a ratio of 3:2 (CD:UC) and the average age of diagnosis was similar in all races, 26.4 
yr.    Nguyen et al. (2006) investigated the degree to which family history occurred across these 
three groups first by examining the prevalence of IBD family history across all subjects which was 
reported at 25.6% (95% IC: 23-28%).  Then prevalence of family history was broken down by 
race: white = 28.6%, AA = 18.1%, Hispanic 16.6%.  Nguyen et al. (2006) believed that underlying 
genetic differences between racial groups and ascertainment bias could possibly explain the lower 
prevalence of family history among AA and Hispanics compared to the white cohort; however, 
the findings of this study were consistent with the findings of previous research in studies of 
children with IBD (Kugathasan et al. 2005; Eidelwein et al. 2005).     
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Next the researchers broke down family history based on diagnosis.  In cases of UC there 
was no statistical difference between the racial groups.  Conversely in cases of CD, the data showed 
white subjects were more likely to have a family history of IBD, 30.6%, compared to AA subjects, 
19.8%.  Hispanics had an even lower prevalence compared to white subjects, 17.9% vs. 30.6%, 
respectively.  This study found that there are racial differences in IBD phenotype and that the 
underlying causal genes are most likely not universal either. 
4.2 TWIN STUDIES 
Twin studies are an integral part of genetic research.  Twin studies that show increased 
concordance rates in monozygotic (MZ) compared to dizygotic twins (DZ) is evidence of an 
underlying genetic factor that is attributing to disease.  IBD Twin studies have reported an elevated 
concordance amongst MZ twins, 6% - 15% for UC and 30% - 37% for CD. The larger percentage 
of concordance in CD twins compared to UC twins suggests there is a stronger genetic component 
underlying the onset of CD (Conrad et al. 2014; Russell and Satsangi 2004; Ordas et al. 2012; 
Brant 2011). Because concordance is not 100%, extraneous factors such as environmental 
exposures are still worth investigating in regards to the onset of IBD (Brant 2011; Conrad et al. 
2014).  Twin studies have also been used to investigate the effects of smoking and disease onset.  
One study found that amongst Swedish and Dutch IBD twin cohorts, smoking revealed a 5 fold 
protective effect in cases of UC discordant MZ twins  (Brant 2011).  The success of twin studies 
provided the confidence needed to take research to the next level, molecular genetics, in an attempt 
to find causal genes.  
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 4.3 GENOME WIDE ASSOCIATION STUDIES 
In cases of non-Mendelian disease, family and twin studies can only provide so much direction 
and clarity.  Genome Wide Association studies (GWAS), utilizes registries of multiplex families 
and seek linkage that is greater than that expected by chance association (Konda et al. 2006).  
GWAS studies operate under the hypothesis ‘common disease, common variant’, meaning if a 
disease is common, then any associated risk alleles will appear in more than 1-5% of the population 
(Manolio et al. 2009). While GWAS is better at detecting weak associations compared to linkage 
studies it still cannot direct casual information; however, it has proven to be the most effective 
way to identify IBD candidate genes worth further investigation. 
Jostins et al. (2012) article was a landmark meta-analysis of 15 GWA studies, from which 
the data was validated with a custom SNP array called the Immunochip. The Immunochip contains 
almost 200,000 SNPs and >700 small insertion–deletions identified by previous GWAS loci for 
12 immune-mediated diseases—Crohn's disease, ulcerative colitis, coeliac disease, type 1 diabetes 
mellitus, psoriasis, ankylosing spondylitis, multiple sclerosis, rheumatoid arthritis, IgA deficiency, 
autoimmune thyroid disease, primary biliary cirrhosis and systemic lupus erythematosus.  A total 
of 186 loci were studied using SNP information from the 1,000 Genomes project.  However it 
should be noted that genetic variation of individuals of non-European origin is under-represented 
in this array (Van Limbergen, J., et al 2014).  
The Immunochip gave Jostins et al. (2012) more power as it enlarged the sample size to 
included 40,000 IBD genomes for verification.  And as a result allowed Jostins et al. (2012) 
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research to bring the total number of risk loci from 92 to 163.   They also found 110 loci associated 
with both UC and CD, while 23 were UC specific and 30 were CD specific. Two risk loci for CD 
were protective against UC, PTPN22 and NOD2, which would suggest CD and UC have different 
biological mechanisms.   The great degree of overlapping loci suggests nearly all biological 
mechanisms involved in one disease are also involved in some capacity in the other.  
Previous GWA studies only covered relatively common genetic variants by utilizing a 
significance threshold of >1% frequency with in the population, which can fail to capture the 
variant with a rare allele frequency  (Graham and Xavier 2013).   Jostins et al. (2012) was able to 
identify candidate genes in 53% of the 163 loci, almost twice as many as previous studies.  
However, only 29 SNPs showed LD to variants in the 1000 Genomes Project data, which supports 
the theory that a majority of the genetics of IBD lays within non-coding regions of the genome.   
Variants in the noncoding regions tend to alter gene expression; therefore, gene expression may 
be a key to understanding the mechanisms underlying the onset of IBD (Graham and Xavier 2013).    
Also these risk variants of noncoding regions make functional interpretation challenging in turn 
making it difficult to identify genotypes that relate to particular pathway associated phenotypes 
(Kaser and Pasaniue 2014). 
4.3.1 Parent-of-Origin Effect 
Fransen et al. (2012) investigated the possibility of a parent-of-origin (POO) effect in the 2012 
paper “Limited Evidence for Parent-of-Origin Effects in Inflammatory Bowel Disease Associated 
Loci.”  The authors believe that genomic imprinting could explain some of the “missing 
heritability” seen within IBD. The authors’ reasoning for a possible POO effect is the observation 
that, children with CD mothers were at a higher risk for developing CD than were children of 
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fathers with CD and proposed that this finding could be explained by either inactivation of the 
paternal allele by genomic imprinting or the mother’s diet or genotype could have an affect on the 
developing fetus, where maternal proteins or circulating RNA pass through the placenta and 
influence the fetal epigenome.   
They looked for POO effects in two cohorts of IBD patients: one Dutch and one Indian.  
Subjects were genotyped using the iCHIP (Immunochip) through Illumina Inc., and combined the 
UC and CD trios and investigated the known 28 overlapping loci.   The authors state they had 
significant power; however, their results were only “nominally significant” for genes IL12B and 
PRDM1 in the Dutch UC+CD cohort; NOD2 in the Dutch CD cohort; and IL10 in the Indian UC 
cohort.   Findings could not be replicated outside of the cohort in which they were found.  In the 
end the authors state that while POO effects could not be determined at this time, it is possible in 
the future, with better technology and larger family cohorts a POO effect may be discovered 
(Fransen et al. 2012). 
4.4 GENETICS AND PATHOGENESIS 
Thus far data from GWA studies has identified 163 loci associated with at least 300 known genes, 
linking back to roughly 56 biological pathways mainly related in some way to the immune system, 
especially the mucosal immune system and microbial interactions.  (Jostins et al. 2012; Dinwiddie 
et al. 2013).  Table 7. below shows a portion of identified IBD genes and their pathway 
involvement. 
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Table 7. IBD Genes Categorized by Disease Association and Pathway Involvement 
IBD-related Processes UC genes CD genes UC/CD genes Total 
T-cell regulation 
IL2, TNFRFSFP, 
PIM3, IL7R, 
TNFSF8, IFNG, 
IL21 
NDFIP1, TAGAP, 
IL2RA 
TNFSF8, IL12B, 
IL23R, PRDM1, 
ICOSLG 
15 
Restitution ERRFI1, HNF4A, PLA2G2A/E STAT3 
NKX2-3, RTEL1, 
PTGER4 9 
Immune cell recruitment IL8RA/IL8RB CCL11/CCL2/CCL7/CCL8, CCR6 MST1 8 
Solute transport AQP12A/B, SLC9A3, SLC26A3 
SLC9A4, SLC22A5, 
SLC22A4 0 7 
Innate mucosal defense SLC11A1, FCGR2A/B NOD2, ILTN1 CARD9, REL 7 
Il-23/Th17 IL21 STAT3 IL23R, JAK2, TYK2, ICOSLG, TNFSF15 7 
Immune Tolerance IL1R1 / IL1R2 IL27, SBNO2, NOD2 CREM, IL10 7 
Epithelial barrier ECM1, HNF4A, CDH1, GNA12 MUC19, ITLN1 0 6 
B-cell regulation IL7R, IRF5 IL5, IKZFI, BACH2 0 5 
Paneth cells 0 ITLN1, NOD2, ATG16L1 XBP1 4 
Antigen presentation 0 ERAP2, LNPEP, DENND1B 0 3 
Oxidative stress HSPA6, DLD, PARK7 
PRDX5, BACH2, 
ADO, GPX4, 
GPX1, SLC22A4, 
LRRK2, NOD2 
UTS2, PEX13, 
CARD9 14 
Autophagy PARK7, DAP ATG16L1, IRGM, NOD2, LRRK2 CUL2 7 
Intracellular logistics TTLL8, CEP72, TPPP VAMP3, FGFR10P KIF21B 6 
Apoptosis/necroptosis DAP FASLG, THADA PUS10, MST1 5 
ER stress SERINC3 CPEB4 ORMDL3, XBP1 4 
Cell migration ARPC2, LSP1, AAMP 0 0 3 
Carbohydrate metabolism 0 GCKR SLC2A4RG 3 
 
 
 
The information for this table was adapted from Khor et al. (2011) and presents a portion of known IBD 
genes and their pathway and disease involvement.  
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One of the most significant findings is that genes involved in maintenance of the mucosal barrier 
tend to be UC specific while microbial recognition factors; specifically, autophagy, and innate 
immune system microbial recognition processing appear to be CD specific.  This coincides with 
the histological findings that UC inflammation remains in the superficial layers of the mucosal 
epithelial, while CD inflammation is found in the deeper layers penetrating into the lumen (Danese 
and Fiocchi 2011; Parkes 2012).   
Jostins et al. (2012) explains that 70% of the IBD loci are shared with other complex 
diseases, many of them, more than would be expected by chance, are associated with immune-
mediated disease, including those of an auto-inflammatory nature (Jostins et al. 2012; Knights et 
al. 2013). Table 8. Below is a sample of the shared loci between autoimmune disorders and IBD. 
 
Table 8. Genetic Overlap of Autoimmune Diseases and IBD 
Disease Name IBD genes CD genes UC genes Total 
Coeliac Disease 5 6 2 13 
Type 1 Diabetes 4 5 1 10 
Rheumatoid Arthritis 2 3 4 9 
Systemic Lupus 
Erythematosus 3 1 2 6 
Multiple Sclerosis 2 1 2 5 
Type 2 Diabetes 1 2 2 5 
Alopecia 0 2 2 4 
Asthma 2 2 0 4 
Vitiligo 0 4 0 4 
Leprosy 1 2 0 3 
Ankylosing Spondylitis 1 1 0 2 
Behcet's 2 0 0 2 
Atopic dermatitis 1 0 0 1 
 
The information in this table is adapted from Lees, C.W., et al. (2011) and presents the number of IBD genes that 
overlap with other autoimmune diseases.  
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4.4.1 IBD and the Immune System 
The exact understanding of the underlying pathogenesis involved in IBD is still under 
investigation.  One suggested theory is that defects in the epithelial barrier allow an excessive 
number of microbes into the lamina propria triggering the immune response causing an over 
activation of the mechanisms used to mediate the immune/inflammatory response.  In the 
following sections this paper will discuss a few areas of both the innate and adaptive immune 
systems and how dysregulation of certain components can be related back to the clinical findings 
of patients with IBD.  
4.4.1.1 Defensins 
Defensins are antimicrobial peptides with the ability to destroy Gram-negative and Gram-positive 
bacteria, fungi, yeasts, parasites and viruses.  Defensins are part of the non-specific, innate immune 
response and therefore are indiscriminate in their attack.   Two key factors allow defensins to attack 
pathogens and not host cells.  First host cell membranes contain cholesterol and defensins appear 
to avoid attacking cells containing cholesterol.  Second, pathogens contain specific external 
molecules that are unique to them and are not found on host cells called pathogen-associated 
molecules or pathogen-associated immuo-stimulants.  When a defensin comes into contact with 
this type of molecule both the inflammatory response and phagocytosis are utilized to remove the 
pathogen.  Phagocytosis utilizes neutrophils and macrophages to envelope and destroy the 
pathogen (Alberts et al. 2002).  In colonic biopsy samples of UC patients expression of selected 
human beta-defensins are up-regulated.  What exactly causes this increase in defensin production 
is still unclear (Ordas et al 2012). 
 42 
4.4.1.2 Dendritic Cells 
Dendritic cells are also part of the innate immune system and fill two roles: first removal of 
pathogens via phagocytosis and second acting as antigen-presenting cells used to activate T-cells 
of the adaptive immune system (Alberts et al. 2002).  The number and stimulatory capacity of 
activated and mature dendritic cells are elevated in UC patients and circulating numbers of 
dendritic cells show a positive correlation to disease activity; suggesting these cells are part of the 
mechanism that causes inflammatory perpetuation in UC (Ordas et al. 2012).  What perpetuates 
this activation of dendritic cells is still unclear. 
4.4.1.3 Toll-like Receptors 
Toll-like receptors (TLR) are found on the surface of macrophages, neutrophils and the lining of 
the lung and mucosal surface digestive tract.  They are the body’s alarm system and alter both the 
innate and adaptive immune systems.  When a pathogen-associated immune-stimulant adheres to 
a TLR, signals are sent for phagocytosis to occur and changes in gene expression stimulate the 
innate immune response known as the complement cascade (Alberts et al. 2002).   
TLR4 expression is extremely uncommon in healthy controls; however, TLR4 expression 
is substantially increased in lamina propria cells of patients with ulcerative colitis.  Suggesting 
changes in TLR genes (i.e. TLR4 D299G polymorphism) can alter susceptibility to enteric 
infections or cause the host to lose tolerance to commensal bacteria triggering the adaptive immune 
response (Ordas et al. 2012). 
4.4.1.4 NF-kB pathway 
Not all foreign bodies that come into contact with the host are pathogenic; one example is food.  
A food allergy is when the body mistakes food for a pathogen and initiates the adaptive immune 
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response every time that food is eaten (Alberts et al. 2002).   An autoimmune disease is when the 
adaptive immune response losses its ability to distinguish host cells from pathogen cells.  In a 
person who does not have IBD it is hypothesized that commensal bacteria helps the immune 
system by down regulating the inflammatory genes, blocking the NF-kB pathway from being 
activated.  This is what allows a person to not have an inflammatory response every time we come 
into contact with harmless bacteria.  In a person with IBD exposure of commensal bacteria does 
trigger an inflammatory response and the NF-kB pathway is not inhibited and researchers are 
attempting to determine exactly how this occurs (Hanauer 2006).  In a healthy individual, 
commensal bacteria turns off inflammatory genes by blocking ubiquitination and inhibiting the 
NF-kB pathway from progressing.  When pathogenic bacteria bind to a toll-like receptor (TLR) 
on the cell surface inflammatory factors connected to the NF-kB pathway are generated and  
intermediate kinases are stimulated, leading to phosphorylation of the inhibitor of B kinase and 
subsequent dissociation of NF-kB protein which is then moved to the nucleus switching on 
inflammatory genes such as; interleukin receptor–associated kinase; myeloid differentiation factor 
toll/interleukin-1 receptor; then allowing ubiquitination to occur (Hanauer 2006).  However, in an 
individual with IBD it is believed that this pathogenic response is some how activated by 
commensal bacteria which are abundant in the gut therefore resulting in a continuous and 
destructive response.  
4.5 PHARMACOGENETICS 
Attempts have been made to find pharmacogenetic factors that may translate to better medical 
management as a shift towards personalized medicine becomes more attainable.  Currently 
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clinicians utilize TPMT (thiopurine methyl-transferase) genotyping or enzymatic analysis to 
determine the efficacy of using thiopurine drug therapy such as Azathioprine. There are two alleles 
associated with TPMT, H (high), and L (low), which present in an autosomal co-dominant 
inheritance pattern.  Individuals who are H/H (wild type) have high enzyme activity and can 
metabolize full dose regimens of therapy.  H/L heterozygotes have intermediate enzyme activity 
and should receive a reduced recommended dose.  These individuals may be at risk for 
myelosupression.  Finally, L/L homozygotes have low to no enzyme activity, recommended dosing 
may cause 6-MP cytotoxicity and these individuals are at the highest risk for life-threatening 
myelosuppression; therefore, thiopurine therapy is not recommended (Weinshilboum and Sladek 
1980; Prometheus Therapeutics & Diagnostics 2014).  
Variants of the MDR1, TNF and migration inhibitory factor genes have been linked to 
corticosteroid refractoriness or sensitivity in CD and UC.  MDR1 has also been associated with a 
higher risk of cyclosporine failure in patients with steroid-resistant UC (Beaugerie and Sokol 
2012).  Response to Infliximab seems to vary between IL23R homozygous risk increasing and risk 
decreasing carriers with the homozygous risk increasing variants more likely to be treatment 
responders (Beaugerie and Sokol 2012). 
 
4.6 IBD AND GENETIC COUNSELING 
Genetic counselors want to be able to provide their patients with genetic testing options that can 
provide prognostic information, statistics about recurrence risks for future pregnancies and disease 
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susceptibility for unaffected family members.  However in situations of non-Mendelian disease 
this information is either not accessible or lacks clinical utility.  
4.6.1 Risk to Family Members 
Russell and Satsangi (2004), published a well-researched review of 20 family studies ranging from 
1980 to 2002 and 4 major European twin studies to determine the familial risks that exists for IBD.  
Russell and Satsangi (2004) found that factors that increased risk were: Ashkenazi Jewish ancestry, 
multiple affected family members, and the proband having CD.  The general risk to a first-degree 
relative for developing IBD is 1 in 10-20 and siblings of IBD probands are at the highest risk for 
developing IBD, with greater risk being associated with CD probands.  The relative risk for CD 
siblings is 25-42 and the relative risk for UC siblings is 8-15.  Offspring of an IBD proband are 
considered to have the next highest risk after siblings, with parents of an IBD proband having the 
lowest risk.   The age of the offspring in question also affects the relative risk as IBD general 
occurs between the ages of 15-30, the risk begins to decrease after the age of 30. When both parents 
have IBD, offspring have at least a 1 in 3 lifetime risk of IBD.  For a monozygotic twin of a CD 
proband the lifetime risk is 1 in 3 for IBD and with a UC proband around 1 in 5.  
In regards to family history CD probands have an affected first-degree relative with CD 
between 2-16% of the time and a relative with IBD 5-22% of the time.  UC probands have an 
affected first degree relative with UC or IBD 5-15% of the time.  Third degree relatives are still at 
an increased risk compared to the general population however it is considerably less than first-
degree relatives (Russell and Satsangi 2004; Orholm et al. 1991; Yang et al. 1993). 
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4.6.2 NOD2 
NOD2, one of the first susceptibility genes identified for CD, is one gene that can offer prognostic 
information for patients and families with a certain level of confidence, as such, for the purposes 
of this paper only NOD2 will be discussed in detail due to its current use in clinical testing. 
NOD2, is involved in host signaling pathways and is associated with activation of nuclear   
factor   (NF)-kB, a   transcription   factor involved   in   cellular   inflammatory   responses and 
macrophage apoptosis.  Mutations in NOD2 reduce activation in (NF)-kB disrupting the 
development of commensal bacteria tolerance.  Lack of NOD2 expression in intestinal epithelial 
cells, reduces the host’s normal response to microbial byproducts, causing overgrowth of bacteria 
and a greater potential for a breakdown in the mucosal barrier.   It is also suggested that NOD2 
variants disrupt mucosal homeostasis by affecting the formation of regulatory and effector T cell 
responses (Hanauer 2006).   
NOD2 is the most well studied IBD gene and is the only gene to have significant prognostic 
information (Cho and Brant 2011).  NOD2 has been associated with ilieal involvement and a more 
aggressive clinical course of CD; i.e., higher risk of intestinal strictures, earlier need for first 
surgery and reduced postoperative disease-free interval (Beaugerie and Sokol 2012; Benitez et al. 
2014).  NOD2 has also been shown to be a protective factor against the development of UC  (Van 
Limbergen et al. 2014). 
The three major risk alleles for NOD 2 are: SNP 8 (R702W) [C2104T], SNP 12 (G908R) 
[G2722C] and SNP 13 (1007fs) [3020insC] (Prometheus Therapeutics & Diagnostics 2014).   The 
prevalence of CD is about 20 in 10,000 (0.2%) in either Europe or North America and roughly 7 
out of 20 will have NOD2 variants.  Roughly 30% of CD cases from the Western world carry at 
least one of the three major risk alleles and individuals with at least one of those variants has a 3 
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to 4 fold increased risk to develop CD.  Overall, 10% of individuals with a NOD2 variant will not 
have IBD (Rogler 2011).      
Results of a NOD2 gene test may not accurately represent the risk to an individual who is 
not of a European ancestry as previous studies have found that NOD2 risk alleles are not universal 
across racial groups (Nguyen et al. 2006).  In a study of 626 Japanese IBD patients and 292 controls 
PCR was used to determine the allele frequencies of the three common NOD2 variants (C2104T, 
G2722C, and 3020insC) found in white populations.  None of the patients were carriers for any of 
the variants investigated (Inoue et al. 2002).  Nguyen et al. (2006) explains that there are also 
significantly lower NOD2 allele frequencies in African Americans compared to white CD patients 
and unaffected white individuals.  
4.6.3 Clinically Available Testing 
The non-diagnostic clinical testing capabilities today consist of genetic, serological and 
inflammatory markers.  The serological markers used are antibody specific and can be useful in 
aiding in the diagnosis of patients with histologically classified IC (Danese and Fiocchi 2011; 
Conrad et al. 2014).  Table 9. below summarizes the laboratories and tests offering IBD associated 
testing. 
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      Table 9. Current Available IBD Testing 
Lab Test Methodology Detection 
Rate 
Gene List Indications 
 
 
 
 
 
Emory 
Genetics 
 
 
 
 
 
Inflammatory Bowel 
Disease: Sequencing 
Panel 
 
 
 
 
 
Next Generation 
Sequencing 
 
 
 
 
 
~99% 
ADAM17, AICDA, ATG16L1, 
BTK, C1orf106, CD40LG,  
COL7A1, CYBA, CYBB,  
DCLRE1C, DOCK8, ERAP2,  
FERMT1, FOXP3, FUT2,  
G6PC3, GUCY2C, HPS1,HPS4,
HPS6, ICOS, IL10, IL10RA,  
IL18RAP, IL23R, IL2RA,  
IRGM, ITGAM, LRBA, MEFV,
MVK, NCF2, NCF4, NOD2,  
PIK3R1, PLCG2, PTEN,  
PTPN22, RAC2,RB1, RET,  
SH2D1A, SLC37A4, STAT1,  
STXBP2, TTC37, WAS, XIAP 
 
 
 
 
Very early onset IBD or 
IBD-like intestinal 
inflammation. 
 
 
 
Quest 
Diagnostics 
 
 
 
Inflammatory Bowel 
Disease 
Differentiation Panel 
 
 
 
 
Immunoassay 
pANCA+/AS
CA– 50% 
sensitive and 
35% specific 
for UC 
ANCA screen with reflex to 
ANCA Titer, 
Myeloperoxidase Ab (MPO), 
Proteinase-3 Antibody, 
Saccharomyces cerevisiae Ab 
(ASCA) IgG, 
Saccharomyces cerevisiae Ab 
(ASCA) IgA 
Intended to aid in the 
diagnosis of Crohn's 
Disease. 
 
A positive pANCA aids 
in the differentiation of 
patients with ulcerative 
colitis 
pANCA–
/ASCA+ 47% 
sensitive and 
31% specific 
for CD 
 
 
Prometheus  
Therapeutics 
and 
Diagnostics 
 
 
 
 
IBD sgi Diagnostic 
 
 
 
Combines 
serologic, genetic 
and inflammation 
markers 
 
Sensitivity:   
IBD 74%      
CD 89%      
UC 98% 
Serological Markers: anti-Fla-
X, anti-A4-Fla2, anti-CBir1, 
anti-OMPC, and DNAse-
sensitive pANCA 
 
 
Aids healthcare 
providers in 
differentiating 
IBD vs non-IBD and 
CD vs UC 
 
Specificity:   
IBD 90%     
CD 81%      
UC 84% 
Genes: ATG16L1, STAT3, 
NKX2-3, ECM1 
Inflammation Markers: VEGF, 
ICAM, VCAM, CRP, SAA 
 
Prometheus  
Therapeutics 
and 
Diagnostics 
 
 
Crohn’s Prognostic 
 
 
Serologic and 
Genetic markers 
 
 
Not provided 
Serologic Markers: anti-CBir1, 
anti-OMPC, and DNAse-
sensitive pANCA 
 
Quantifies a patients 
individual probability 
of developing disease 
complications over time Genes: NOD2 variants SNPs 
8,12,13 
Center for 
Genetics at 
Saint 
Francis 
 
Crohn’s Disease - 
NOD2/CARD15 
Complete Gene 
Analysis 
 
Bi-directional 
Sanger Sequence 
Analysis 
 
 
99% Gene: NOD2/CARD15 
 
Identify any gene 
variants 
Prometheus  
Therapeutics 
and 
Diagnostics 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene: TPMT (thiopurine 
methyltransferase)  
 
Genotypes:   
High/High = normal enzyme 
activity    High/Low = 
intermediate activity                        
Low/Low = low to no activity 
 
 
 
 
 
 
A qualitative 
evaluation, to determine 
Baylor 
Medical 
Genetics 
Laboratory 
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 4.6.3.1 Serological Markers 
High levels of neutrophil activity are common in cases of UC and Crohn’s colitis although is not 
typical in classic CD cases.  Perinuclear anti-neutrophil antibody (pANCA) or atypical ANCA 
(xANCA) reactivity is found in 50 – 70% of UC patients compared to 10% of CD cases (Conrad 
et al 2014).   A yeast antibody called Anti-Saccharomyces cerevisiae (ASCA, glycan antibody) is 
more reactive in CD vs. UC cases (Beaugerie and Sokol 2012).  Anti-goblet cell antibody (GAB) 
is another UC specific marker occurring in 15–28% of UC patients (Conrad et al. 2014). 
Three additional markers are used to identify antibodies to specific bacteria.  “ . . . 
Escherichia coli outer-membrane porin C  (OmpC), Pseudomonas fluorescens CD-related protein 
(anti-12) and the CBir1 flagellin (CBir1).” (Beaugerie and Sokol 2012).  Specific combinations of 
these markers can provide information regarding not only disease type but also behavior, i.e. 
reactivity to the three bacteria antibodies plus ASCA is associated with not just CD but early 
disease onset and need for small bowel surgery  (Beaugerie and Sokol 2012).   
Molecular 
Genetics 
Laboratory 
Cincinnati 
Children’s 
Hospital 
TPMT Genotype or 
Enzymatic 
Analysis 
99% Enzyme:  thiopurine S-
methyltransferase       
 
Reference Range: Normal 
Activity: >21.0 EU/mL           - 
Intermediate Activity: 6.0 - 21.0 
EU/mL                          - Low 
Activity: <6.0 EU/mL 
a patient’s ability to 
utilize thiopurine drug 
therapy 
Laboratory 
Boston 
Children’s 
Hospital 
The information in the above table displays the available IBD testing in the US. Data for this table was collected from 
the following websites: NCBI GTR: Genetic Testing Registry, Quest Diagnostics, Emory Laboratory, and Prometheus 
Therapeutics and Diagnostics.   
   
Table 9. Continued 
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4.6.3.2 Laboratory findings 
Laboratory features (elevated ESG, CRP and faecal calprotectin) are not disease specific markers 
but rather indicators for general inflammation and deficiencies due to malnutrition (iron 
deficiency, anaemia) but can be helpful in assessing disease activity (Conrad et al. 2014). 
4.6.4 Validity of Current Testing  
Genetic testing is very useful in Mendelian genetic disorders, such as cystic fibrosis, in which 
changes in a single known gene lead to disease symptoms. Genetic test results in these cases 
provide a molecular diagnosis, sometimes even in an asymptomatic individual. However, a 
diagnosis of IBD cannot be made from a genetic test alone; it still relies on the incorporation of 
clinical signs and symptoms. This limitation makes a diagnosis of an asymptomatic individual 
through genetic testing impossible. Furthermore, current genetic testing for IBD remains 
invalidated minimizing its clinical utility even in symptomatic individuals. 
Gerich and McGovern (2014) explain that the general population prevalence of IBD is 
about 0.6%, which correlates into a low pre-test probability for the average person.  In an 
individual with IBD, the utility of testing is small, as the available methods are not considered 
diagnostic and colonoscopy and endoscopy are still needed to make a diagnosis.  They also 
presents an interesting example pertaining to familial IBD stating that not all IBD associated SNPs 
correlate directly to disease in any given individual.  They demonstrate this in a hypothetical but 
plausible scenario of a mother and daughter with CD, the daughter has a NOD2 disease-associated 
variant and the mother does not, suggesting that the daughter’s CD is obviously not caused by a 
NOD2 mutation and in that case possibly neither is the mother’s.   In this case the daughter’s ‘risk 
score’ would not have been a true reflection of her genetic risk (Gerich and McGovern 2014).  In 
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conclusion, they states until high power studies can validate predictive phenotype – genotype 
findings it is premature to offer any kind of direct to consumer testing.  
Danese and Fiocchi (2011) state that genetic screening for UC would be more useful if the 
there were fewer implicated genes and those genes had greater effect sizes.  Lissner and Siegmund 
(2013) discuss the need for better risk stratification in order to separate high risk from low risk 
individuals and that current biomarkers cannot provide a valid stratification model. 
 
4.6.5 Cancer Risks 
The primary cancer risk associated with IBD is colorectal cancer (CRC).  Individuals with a 
diagnosis of UC are more likely to develop CRC than individuals with CD. Margo et al. (2013) 
states that the incidence of CRC is approximately 4/1000 per person year of disease and the average 
prevalence is 3.5%.  
Other factors that increase CRC risk are disease location and severity.  Individuals with 
pancolitis or Crohn’s colitis are more likely to develop CRC.  A younger age at diagnosis, presence 
of PSC, a family history of CRC (independent of IBD), and the presence of pseudopolyps all 
increase the CRC risk. Duration of disease is a crucial factor with risk increasing at a rate of .5 to 
1% per year starting 8 to 10 years after diagnosis (Cummings and Rubin 2006; Margo et al. 2013).  
Cummings and Rubin (2006) suggest that the risk may be modified by undergoing cancer 
surveillance colonoscopy with biopsies every one to three years.  
Individuals with CD can be at risk for the rare case of small bowel carcinoma, with lesions 
typically occurring in the distal jejunum and ileum (Margo et al. 2013; Cummings and Rubin 
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2006).  Margo et al. (2013) explains that due to the rarity of developing this type of cancer 
surveillance is not recommended.  
4.6.6 Psychosocial Considerations 
The majority of IBD cases result in a mild disease course, allowing many individuals to lead a 
normal life with minimal disturbances and ability to reach their social and professional life goals 
(Ordas et al. 2012; Cummings and Rubin 2006). 
For more severely affected patients medical intervention is critical for obtaining a normal 
life; however, because of the heterogeneity of IBD, treatments are not always effective and disease 
symptoms can weigh heavily on all aspects of a person’s life.  Simple things such as traveling 
outside the home, social activities with friends and especially eating out may be difficult or nearly 
impossible, which may lead to feelings of depression and anxiety.  The potential inability to work, 
attend school or take care of one’s family can also become great stressors in the life of an individual 
with severe IBD.  It is important as a genetic counselor to be aware of these issues and provide 
appropriate support and resources for these patients. 
There are many national support services and resources available to IBD patients.  The 
most prominent resource in the IBD community is the Crohn’s and Colitis Federation of America 
(CCFA).  Founded in 1967, this non-profit organization is a large financial contributor to IBD 
research and provides the latest educational and support services for patients and families.  The 
CCFA offers 40 support groups nationwide that provide those with IBD the opportunity to meet 
and share information.  There is a connecting database specifically designed for college students 
to meet other college students with IBD.  A mobile diary app called “GI Buddy” was created to 
help patients keep track of symptoms and medications.  
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Over 200 Facebook pages and groups are dedicated to connecting those with IBD, Crohn’s 
and/or UC.  Individuals also reach out through YouTube, an online video sharing website to in an 
attempt to connect and share information.  This type of patient-to-patient communication can be 
very helpful to reduce the feelings of isolation, anxiety and depression that may be accompanied 
by IBD.  Patients also utilize these portals to discuss the benefits and side effects of different 
medications, or diet trends like the Specific Carbohydrate Diet and juicing recipes.  In whatever 
way a patient chooses to access support, it is important to remind him or her to utilize these portals 
with caution and to always verify any medical information they discover with their doctor. 
Another consideration to note is that conversations about bowel movements may be 
embarrassing, and it is not uncommon for individuals (especially children) to hide or ignore their 
symptoms.  Lack of medical attention is especially serious in young people, as the disease has been 
shown to progress more rapidly and behave more aggressively in childhood, making parental 
awareness key.  As a genetic counselor, a family history positive for IBD warrants a discussion of 
the risks and early signs and symptoms (loss of appetite, abdominal pain, weight loss, more 
frequent trips to the bathroom and recurrent constipation).  The majority of early-onset cases do 
have positive family histories, and thus a parent personally affected by IBD may be more aware 
than a non-affected parent.  It is always a good idea to discuss with parents what to look for and 
how to open the lines of communication with their children.  
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5.0  FUTURE STUDIES 
As research delves further into the underpinnings of IBD, we are learning that the pathogenesis of 
this disease is strikingly complex.  In order to determine the underlying pathology, we need to gain 
a greater understanding of the cell types involved in the initiation and progression of disease, how 
those cells are regulated and utilized in human tissue, and how they lead to specific phenotypes 
(Knights et al. 2013). 
Due to the number of identified risk loci and the large number of involved pathways, it has 
been suggested that the current method for categorizing individuals (based on clinical 
manifestations) may not be sufficient.  As we begin to unravel the complexities of IBD genetics 
and immune system pathways, we may find that individuals are better categorized by the specific 
pathway that is dysregulated.  Soon there may be several subtypes of UC, several subtypes of CD, 
and previous cases of IC once thought to be “indeterminate” may become a third major category 
of classification (Hanauer 2006).  Patients classified by pathway involvement may invite a 
personalized medicine approach, which touts better and more specific disease treatment that 
ideally targets the underlying cause and not merely the symptoms.    
In addition, further research still needs to assess genetic and serological testing in 
unaffected cohorts of diverse ethnic backgrounds as preliminary research shows lack of 
congruency between European cohorts and other ethnic groups.  There is a great need for all future 
studies to include rigorous phenotype data, especially if classification by pathways begins to create 
new disease subtypes.  Knowing the associated phenotypic features will be necessary for clinical 
application (Benitez et al. 2014).   
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Deeper investigation into the microbiome is greatly needed to answer the question of what 
triggers the loss of tolerance to commensal bacteria.  The answer may lie in the metagenome and 
further study into how it and the host genome interact.  Longitudinal studies cataloguing 
microbiome composition before and after disease will aid in that regard (Jostins et al. 2012; 
Graham and Xavier 2013; Knights et al. 2013).  
A current frustration in genetic research of IBD is that suspected loci do not consistently 
coincide with disease manifestations. It remains unclear if this is an issue of incomplete 
penetrance, polygenic inheritance, or some combination of the two. It has been useful to examine 
genetic variants in both affected and unaffected cohorts to tease out loci that may be appropriate 
for clinical genetic testing.  In the future reliable diagnostic testing will improve treatment efficacy 
or affected individuals but also offer options for surveillance and family planning to both affected 
and unaffected persons.   
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6.0  CONCLUSION 
In conclusion, there are still many unanswered questions about IBD, which can be frustrating for 
both physicians and patients.  The disease has an increasing incidence worldwide, simultaneously 
increasing the number of individuals requiring medical services, time, support and education.  This 
creates a need for medical professionals to accommodate this rapidly expanding patient population, 
and genetic counselors may be an appropriate option. 
The skills of genetic counselors are broad and highly adaptable such that they would be a 
valuable contribution to any IBD clinic or research team.  They are the best individuals to navigate 
the genetics of IBD, which are much more complex than the more straightforward Mendelian 
diseases.  GI physicians, like many other specialists, are under pressure to keep up with constantly 
evolving genetic landscape as well as detection and treatment modalities.  This presents an 
additional time commitment that may be a burden to already overwhelmed GI physicians.  A 
genetic counselor is trained with a capacity to synthesize pertinent research and translate it into 
understandable terms suitable for patients.  This ability to break down complex information can 
be an asset to research coordination as well, assisting research teams in connecting to and educating 
a motivated patient population.   
While current genetic testing options have some clinical utility for affected patients they 
are not yet appropriate for widespread clinical use in unaffected individuals.  The majority of 
genetic research on causative genes has been done on Caucasian populations of European descent 
and replication studies have provided inconsistent findings IBD populations of minority ethnic 
groups.  The failure to identify universal candidate genes reduces the utility of the tests in the 
 57 
minority ethnic groups making the role of a genetic counselor extremely useful in situations where 
genetic testing is being offered to such patients.   
As both the technology and knowledge surrounding IBD genetics continues to expand 
along with the IBD community’s awareness of the benefits and capabilities of genetic testing the 
role of genetic counseling will become more practical and applicable to the GI specialty. 
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